SCHEMBL9610950

SCHEMBL9610950

Cc1ccc(C(=O)Nc2ccc(CN3CCNCC3)c(C(F)(F)F)c2)cc1-c1cnc2cccnn12

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABL1 P00519 14/20 0.75
▸ BCR P11274 2/20 0.65
▸ ABL2 P42684 2/20 0.64
▸ CSF1R P07333 2/20 0.64
▸ KIT P10721 2/20 0.64
▸ EGFR P00533 2/20 0.64
▸ BRAF P15056 2/20 0.64
▸ RET P07949 2/20 0.64
▸ GAK O14976 1/20 0.64
▸ MLNR O43193 1/20 0.64
▸ RIPK2 O43353 1/20 0.64
▸ JAK2 O60674 1/20 0.64
▸ NR1I2 O75469 1/20 0.64
▸ ABCB11 O95342 1/20 0.64
▸ MAP4K4 O95819 1/20 0.64
▸ NR3C1 P04150 1/20 0.64
▸ ERBB2 P04626 1/20 0.64
▸ NTRK1 P04629 1/20 0.64
▸ LCK P06239 1/20 0.64
▸ FYN P06241 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10266091 0.93 ABL1 (0.68) ABL1BCRABL2CSF1RKIT
SCHEMBL9610953 0.92 ABL1 (0.77) ABL1BCRABL2CSF1RKIT
SCHEMBL9610999 0.91 ABL1 (0.76) ABL1BCRABL2CSF1RKIT
SCHEMBL9610934 0.89 ABL1 (0.75) ABL1BCRABL2CSF1RKIT
SCHEMBL10266185 0.88 ABL1 (0.75) ABL1BCRABL2CSF1RKIT
SCHEMBL9610749 0.87 ABL1 (0.64) ABL1BCRABL2CSF1RKIT
SCHEMBL29618190 0.86 ABL1 (1.00) ABL1BCRABL2CSF1RKIT
SCHEMBL588523 0.86 ABL1 (1.00) ABL1BCRABL2CSF1RKIT
SCHEMBL30464941 0.86 ABL1 (1.00) ABL1BCRABL2CSF1RKIT
SCHEMBL10268800 0.85 ABL1 (0.64) ABL1BCRABL2CSF1RKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012139027-A1 METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES ARIAD PHARMACEUTICALS, INC. (US) 2012-10-11 — — WO disclosed
US-20120135986-A1 Bicyclic Heteroaryl Compounds ARIAD PHARMACEUTICALS, INC. (US) 2012-05-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120135986-A1 Bicyclic Heteroaryl Compounds CYP3A43, CYP11B2, CYP2F1 ABL1 110/4885BCR 250/4885ABL2 1006/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback